Ferentinos Panagiotis, Margaritis Dimitrios, Douzenis Athanasios
2nd Department of Psychiatry, University of Athens, Attikon General Hospital, Athens, Greece.
Clin Neuropharmacol. 2016 Nov/Dec;39(6):327-328. doi: 10.1097/WNF.0000000000000194.
Lower urinary tract outflow dysfunction is frequent in older men and a potential cause of serious complications such as acute urinary retention (AUR). Drug-induced AUR has only rarely been reported with selective serotonin reuptake inhibitors including escitalopram; reported cases had no history of urinary outflow dysfunction. We herein report the development of AUR after the introduction of escitalopram at a standard dose in 3 male patients with previously diagnosed or unknown/latent and nonsymptomatic benign prostatic hyperplasia. Urinary retention receded after escitalopram discontinuation in 2 cases but led to emergent prostatectomy in the third. This case series highlights escitalopram's potential association with AUR in elderly men with known or latent benign prostatic hyperplasia. Further studies are warranted to investigate whether compromised or marginal urinary outflow should be considered a contraindication for treatment with escitalopram.
下尿路流出道功能障碍在老年男性中很常见，是急性尿潴留（AUR）等严重并发症的潜在原因。包括艾司西酞普兰在内的选择性5-羟色胺再摄取抑制剂引起药物性AUR的报道很少；报告的病例无尿路流出道功能障碍病史。我们在此报告3例先前诊断为或未知/潜伏性且无症状的良性前列腺增生男性患者，在使用标准剂量艾司西酞普兰后发生了AUR。2例患者停用艾司西酞普兰后尿潴留消退，但第3例导致紧急前列腺切除术。该病例系列突出了艾司西酞普兰与已知或潜伏性良性前列腺增生老年男性AUR的潜在关联。有必要进一步研究，以调查尿路流出道受损或处于临界状态是否应被视为艾司西酞普兰治疗的禁忌症。
